Protalix BioTherapeutics (PLX) Current Leases (2019 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Current Leases of $1.4 million for Q1 2026, up 0.56% year-over-year from $1.4 million in Q1 2025, and up 3.54% quarter-over-quarter from $1.4 million in Q4 2025.
Protalix BioTherapeutics (PLX) Current Leases (2019 - 2026) Analysis & Trends
Protalix BioTherapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Current Leases rose 0.56% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (up 0.56% YoY), while the FY2025 annual figure was $1.4 million, down 7.73% from the prior year.
- Current Leases for Q1 2026 stood at $1.4 million, up from $1.4 million in the prior quarter.
- The five-year high for Current Leases was $1.5 million in Q3 2024, with the low at $1.0 million in Q3 2022.
- The 5-year median for Current Leases is $1.4 million (2025), against an average of $1.3 million.
- The sharpest annual moves came in 2022 and 2023: Current Leases slipped 19.03% in 2022, then surged 31.3% in 2023.
- Protalix BioTherapeutics' Current Leases stood at $1.1 million in 2022, then rose by 26.03% to $1.4 million in 2023, then climbed by 6.46% to $1.5 million in 2024, then dropped by 7.73% to $1.4 million in 2025, then grew by 3.54% to $1.4 million in 2026.
- Business Quant data shows PLX's Current Leases at $1.4 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 1.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.67 Mn |
| Mar 31, 2026 | 1.43 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.26 Mn |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 1.24 Mn |
| Dec 31, 2021 | 1.21 Mn |
| Sep 30, 2021 | 1.24 Mn |